Myriad Genetics
Logotype for Myriad Genetics Inc

Myriad Genetics (MYGN) investor relations material

Myriad Genetics 2026 Stephens Annual Investment Conference | NASH2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Myriad Genetics Inc
2026 Stephens Annual Investment Conference | NASH2026 summary18 Nov, 2026

Q3 performance and portfolio changes

  • Prenatal assets sold to LabCorp for $210M cash; transaction expected to close in H1 2027, likely earlier in the half, with 500 employees transitioning.

  • Sale expected to lift revenue growth by >100 bps and gross margin by >500 bps; about one-third of transferring employees support lab operations and COGS.

  • Q3 revenue improved $10M-$12M, with the increase flowing through to adjusted EBITDA; Q2's $11M change-in-estimate/out-of-period revenue impact was immaterial in Q3.

  • Prenatal transition costs and OpEx efficiencies will phase in through 2027; Ascend is a multi-period effort spanning six revenue and cost value streams.

  • Ascend benefits are expected in 2027, with further impact as capabilities scale into 2028.

Hereditary cancer growth and execution

  • Management cited a $2B affected market and $5B unaffected market, with further penetration opportunity in both; rising cancer incidence and stronger guidelines support market growth.

  • NCCN guideline effects are expected to flow gradually into physician practice and payer policies, supporting a market tailwind rather than a specific quarterly volume step-up.

  • Q3 RCM execution improved after Q2 friction; priorities include adapting to prior-authorization changes, automating medical-record retrieval and strengthening payer relationships.

  • 2027 priorities include improving physician experience and RCM execution to support hereditary cancer volumes and revenue.

Precise MRD roadmap

  • Breast MolDX submission was made in mid-July; approval is expected in H1 2027, probably late in the half, based on a 9-12 month review timeline.

  • CRC and renal submissions are planned over the next several months; endometrial and ovarian submissions are expected in late 2027.

  • MRD volume will be metered in 2027, with more significant ramping as multiple indications gain approval and reimbursement broadens.

  • More than a dozen clinical trials are underway; Precise MRD clinical costs are expected to rise in 2027 vs. 2026, with a specialty sales team supporting broader oncology sales.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Myriad Genetics earnings date

Logotype for Myriad Genetics Inc
38th Annual Healthcare Conference2 Dec, 2026
Myriad Genetics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Myriad Genetics earnings date

Logotype for Myriad Genetics Inc
38th Annual Healthcare Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Myriad Genetics, Inc. offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.